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Background
• Preliminary data estimates about 60,000 
influenza deaths and 800,000 hospitalizations 
for the 2017-2018 season (CDC.gov)
• Very limited options for battling influenza 
infection (seasonal vaccination and Tamiflu)
• Current research in our lab focuses on 
developing a new antiviral treatment for 
influenza
• The Polymerase Acidic (PA) influenza protein 
is an appealing target for drug design due to its 
low genetic drift and requirement for influenza 
replication
• Recombinant PA domains have low solubility
Research Question
Due to the protection of a hydrophobic binding 
pocket, does the addition of the PB1 peptide on 
either the N- or C- terminus of the PA protein 









Initial data suggests C-terminal PB1 addition increases the solubility of 
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